Plain-English translation of NCT07216911 on ClinicalTrials.gov ↗ ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether warning labels focused on mental health can help people make safer choices when buying cannabis products. Researchers are comparing how different product descriptions—some that claim mental health benefits, some with warning labels about cannabis and mental health, and some with both—affect what people decide to buy in a simulated online store. The goal is to understand whether mental health-specific warnings can reduce purchases of cannabis products among people with depression or anxiety.
Cannabis products are increasingly marketed as treatments for anxiety and depression, even though long-term use may actually make these conditions worse. The current warning labels on cannabis products focus on generic risks and don't address mental health concerns. This trial exists to see whether better-designed warnings can protect people with anxiety or depression from being misled by marketing claims.
You will visit an online simulated cannabis store and view different product listings with varying descriptions and warning labels, then indicate which products you would consider purchasing. Depending on which group you're assigned to, you'll see different combinations of product claims and mental health warnings. The study involves completing this shopping task and related survey questions; most participation can be done online from home.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States